ArticleFrontiers in immunology2026
CD161 serves as a prognostic biomarker and predicts immunotherapy response in head and neck squamous cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite advances in immune checkpoint inhibitors (ICIs), the prognosis of patients with head and neck squamous cell carcinoma (HNSCC) remains poor, and reliable biomarkers for predicting clinical outcomes are still lacking. CD161, a lectin-like receptor expressed on multiple T-cell subsets, has been reported to inhibit T-cell cytotoxicity; however, its prognostic and immunological significance in HNSCC remains unclear. Methods: We analyzed transcriptomic data from the HNSCC cohort in the TCGA database and four GEO datasets (GSE6631, GSE102349, GSE159067, and GSE103322) to evaluate CD161 expression, its prognostic significance, and its association with immune infiltration and functional pathways. Single-cell RNA sequencing data were used to identify CD161-expressing cell subsets. Differential expression was further validated by immunohistochemistry (IHC) in 20 paired HNSCC and adjacent normal tissues. The association between CD161 expression and immunotherapy response was additionally assessed in an independent cohort of 33 ICI-treated patients. Results: CD161 expression was significantly lower in HNSCC tissues than in normal tissues in the TCGA cohort and the GSE6631 dataset, which was further confirmed by IHC analysis. High CD161 expression was associated with a favorable prognosis, with longer overall survival (OS) and disease-specific survival (DSS), and remained an independent protective factor in multivariate analysis (OS: hazard ratio [HR] = 0.92, 95% confidence interval [CI]: 0.86-0.99, p = 0.019; DSS: HR = 0.86, 95% CI: 0.78-0.96, p = 0.008). CD161 expression correlated with infiltration of CD8 Conclusion: CD161 is downregulated in HNSCC. Higher CD161 expression is associated with favorable prognosis and an immune-inflamed tumor microenvironment, and may predict response to ICI-containing therapy. These findings suggest that CD161 has potential as a prognostic biomarker and may help characterize tumor-immune interactions in HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.